Analyst Joseph Pantginis of H.C.
Sophiris Bio Inc (NASDAQ:SPHS) reported financial results for the three and six months ended June 30, 2017 and key corporate highlights. Key Corporate Highlights: Phase …
Drug maker Sophiris Bio Inc (NASDAQ:SPHS) released its earnings report for the first quarter of 2017 and is one step closer to beginning Phase …
Sophiris Bio Inc (NASDAQ:SPHS) reported first quarter financial results and key corporate highlights. Key Corporate Highlights: Update on Phase 2b Localized Prostate …
Following Sophiris Bio Inc’s (NASDAQ:SPHS) fourth-quarter and 2016 financial results released yesterday coupled with last week’s update on its prostate cancer program, Rodman …
Sophiris Bio Inc (NASDAQ:SPHS) reported fourth quarter and full year 2016 financial results and key corporate highlights. Key Corporate Highlights: Advanced Topsalysin (PRX302) …
In a research released Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS), with a price target …
Sophiris Bio Inc (NASDAQ:SPHS) shares are rising almost 17% on back of Rodman & Renshaw analyst Joseph Pantginis initiating coverage on SPHS with …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS) with …
Sophiris Bio Inc (NASDAQ:SPHS) announced financial results for the three and nine months ended September 30, 2016. Business Highlights: On August 26, 2016, …